Our data provided evidence indicating that the interplay between SKP2 and FOXA1, and not just SKP2 or FOXA1 levels alone, are better indicators of PCa prognosis, highlighting the significance of SKP2–FOXA1 interactions as a potential biomarker for severe PCa. This evidence concerns the gene SKP2 and posterior cortical atrophy.